TABLE 1.
Studies and participants' characteristics.
| Author, year | Sample size | Gender | Group | Group size (N) | Retention rate (%) | Mean age (years) | Mean BMI (kg m−2) | Treatment phase | Cancer | Cancer stage |
|---|---|---|---|---|---|---|---|---|---|---|
| An et al. 32 | 287 | F |
STAN HIGH COMB |
92 95 100 |
93.3 |
49.6 ± 7.9 49.9 ± 8.6 50.4 ± 9.4 |
25.9 ± 5.0 25.2 ± 4.5 28.1 ± 6.6 |
On | Breast | I‐IIIA |
| Bryant et al. 38 | 17 | M/F |
COMB CG |
8 9 |
94.4 |
52 ± 13 49 ± 15 |
27.1 ± 3.4 29.6 ± 7.3 |
On | Leukemia | n/a |
| Cheville et al. 39 | 56 | M/F |
COMB CG |
26 30 |
84.8 | 63.8 ± 12.5 | n/a | On | Lung, colorectal | IV |
| Coleman et al. 40 | 12 | M/F |
COMB CG |
9 3 |
– | 55 (42–74) a , b | n/a | On | Multiple myeloma | n/a |
| Courneya et al. 33 | 296 | F |
STAN HIGH COMB |
95 99 102 |
98.3 |
49.5 ± 8.0 49.9 ± 8.7 50.4 ± 9.4 |
26.1 ± 4.9 25.2 ± 4.5 28.3 ± 6.6 |
On | Breast | I‐IIIc |
| Demmelmaier et al. 41 | 192 | M/F |
HI‐COMB LMI‐COMB |
95 97 |
66.7 |
58.1 ± 11.4 59.6 ± 11.8 |
n/a | On | Breast, prostate, colorectal | n/a |
| Dieli‐Conwright et al. 34 | 91 | F |
COMB CG |
46 45 |
91 | 53.5 ± 10.4 b | n/a | Off | Breast | 0–III |
| Galvao et al. 29 | 57 | M |
COMB CG |
29 28 |
100 |
69.5 ± 7.3 70.1 ± 7.3 |
27.4 ± 3.2 28 ± 3.8 |
On | Prostate | n/a |
| Hacker et al. 42 | 17 | M/F |
RT CG |
8 9 |
89.5 | 46.3 ± 16.2 b | n/a | On | Hematopoietic stem cell transplantation | n/a |
| Jensen et al. 43 | 21 | M/F |
RT AT |
11 10 |
80.8 |
58.7 ± 12.0 51.6 ± 13.6 |
n/a | On | Gastric, colorectal, pancreatic, and biliary tract | n/a |
| Knols et al. 44 | 131 | M/F |
COMB CG |
64 67 |
100 |
46.7 ± 13.7 46.6 ± 12.0 |
22.9 ± 4.3 23.9 ± 4.0 |
On | Leukemia, lymphoma | n/a |
| Langlais et al. 30 | 21 | M |
AT RT CG |
6 5 10 |
84 | 71 (51–84) a , b | n/a | On | Prostate | Metastatic |
| Owusu et al. 35 | 192 | F |
COMB CG |
94 98 |
90 |
71.81 ± 5.99 71.9 ± 5.82 |
29.8 ± 6.43 30.2 ± 6.90 |
Off | Breast | I‐III |
| Piraux et al. 31 | 72 | M |
RT HIIT CG |
24 24 24 |
92 |
67.9 ± 7.1 67.4 ± 8.9 71.9 ± 8.1 |
26.1 ± 2.9 26.5 ± 3.9 25.8 ± 4.4 |
On | Prostate | n/a |
| Piraux et al. 45 | 18 | M/F |
RT HIIT CG |
6 6 6 |
100 |
61.5 (52.8; 73.5) b 61.0 (54.5; 65.3) b 64.5 (62.5; 72.5) b |
27.0 (24.4; 30.1) b 27.0 (25.4; 31.0) b 25.3 (23.3; 28.3) b |
On | Rectal | II‐III |
| Schmidt et al. 36 | 67 | F |
RT AT CG |
21 20 26 |
83 |
53 ± 12.55 56 ± 10.15 54 ± 11.19 |
n/a | On | Breast | Primary moderate‐ or high‐risk |
| Sprod et al. 46 | 38 | M/F |
COMB CG |
19 19 |
95 |
56.6 ± 13.7 63.3 ± 9.4 |
28.7 ± 5.4 31.3 ± 6.8 |
On | Prostate, breast | Early‐stage with no metastases/recurrence |
| Steindorf et al. 37 | 160 | F |
RT CG |
80 80 |
100 |
55 ± 9.4 56.2 ± 8.6 |
<25 = 64 25–<30 = 62 30+ = 34 | On | Breast | 0–III |
| Steindorf et al. 47 | 47 | M/F |
RT1 RT2 CG |
9 21 17 |
72 |
62.8 ± 6.4 61 ± 9.3 58.7 ± 8.4 |
23.5 ± 3.1 22.4 ± 2.9 25.5 ± 5.6 |
On | Pancreatic | I–IV |
| van Vulpen et al. 48 | 110 | M/F |
COMB CG |
54 56 |
92 |
64.3 ± 7.8 63.1 ± 8.5 |
24.8 ± 3.2 25 ± 3.8 |
On | Esophageal | I–III |
| Zhao et al. 49 | 18 | M/F |
COMB CG |
11 7 |
90 | 57 b |
30 ± 5 32 ± 3 |
On | Head, neck | n/a |
Abbreviations: AT, aerobic training; CG, control group; COMB, combined aerobic and resistance training; HI–COMB, high‐intensity resistance and endurance training; LMI–COMB, low‐to‐moderate intensity resistance and endurance training; Retention rate, the percentage of participants retained at post‐test; RT, resistance training; STAN, standard dose of aerobic exercise, following the Physical Activity Guidelines for Americans endorsed for cancer survivors by the American College of Sports Medicine and the American Cancer Society.
Data are presented as median and interquartile range.
Total sample.